NCT06131489

Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement

Efficacy and Safety of Segmental Resection Combined With the DEP Regimen for Epstein-Barr Virus Associated Hemophagocytic Lymphohistiocytosis With Intestinal Involvement

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 20 (estimated)
• Sponsor: Beijing Friendship Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

EBV-HLH is a rare disease with high mortality, especially for those with intestinal involvement. In order to reduce disease burden and improve survival of these patients, we conduct a prospective observational study to explore the efficacy and safety of segmental resection combined with the DEP regimen.

Detailed description

Epstein-Barr virus associated hemophagocytic lymphohistiocytosis is a rare disease with high mortality, especially for those with intestinal involvement. Some of them still died despite early control of the disease due to severe complications, such as gastrointestinal bleeding. In order to reduce disease burden and improve survival of these patients, we conduct a prospective observational study to explore the efficacy and safety of segmental resection combined with the DEP regimen.

Conditions

• Hemophagocytic Lymphohistiocytosis
• Epstein-Barr Virus
• Bowel Resection

Interventions

Type	Name	Description
OTHER	Segmental bowel resection combined with the DEP regimen	Segmental bowel resection combined with liposomal doxorubicin, etoposide, and methylprednisolone administered in 2 week cycles for 2 cycles

Timeline

• Start date: 2023-12-01
• Primary completion: 2026-12-01
• Completion: 2027-01-01
• First posted: 2023-11-14
• Last updated: 2023-11-14

Locations

1 site across 1 country: China